| 1.25 0.105 (9.17%) | 11-29 13:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.86 | 1-year : | 2.28 |
| Resists | First : | 1.59 | Second : | 1.96 |
| Pivot price | 1.54  |
|||
| Supports | First : | 1 | Second : | 0.83 |
| MAs | MA(5) : | 1.24 |
MA(20) : | 1.62 |
| MA(100) : | 1.99 |
MA(250) : | 2.48 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 19.8 |
D(3) : | 18.7 |
| RSI | RSI(14): 25.5 |
|||
| 52-week | High : | 5.28 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ACXP ] has closed above bottom band by 22.6%. Bollinger Bands are 136.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.15 - 1.16 | 1.16 - 1.16 |
| Low: | 0.99 - 1 | 1 - 1 |
| Close: | 1.13 - 1.15 | 1.15 - 1.16 |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Fri, 29 Nov 2024
Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now - MSN
Thu, 28 Nov 2024
Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Wed, 20 Nov 2024
Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset - cnhinews.com
Wed, 20 Nov 2024
Acurx Pharmaceuticals allocates $1M for Bitcoin reserve - Investing.com
Mon, 18 Nov 2024
ACXP - Acurx Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Thu, 14 Nov 2024
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2024 Earnings Call Transcript - Insider Monkey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 14.8 (%) |
| Held by Institutions | 11.9 (%) |
| Shares Short | 474 (K) |
| Shares Short P.Month | 492 (K) |
| EPS | -1.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.31 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -132.3 % |
| Return on Equity (ttm) | -347 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -1.15 |
| PEG Ratio | 0 |
| Price to Book value | 3.9 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|